Home › Pfizer Announces FDA Acceptance Of And Priority Review Designation For Biologics License Application For Investigational Meningococcal B Vaccine
 

Keywords :   


Pfizer Announces FDA Acceptance Of And Priority Review Designation For Biologics License Application For Investigational Meningococcal B Vaccine

2014-09-03 12:22:48| drugdiscoveryonline Home Page

Pfizer Inc. recently announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bivalent recombinant LP2086 (rLP2086), the company’s vaccine candidate for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in 10 through 25 year olds

Tags: review application license acceptance

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.05Eastern North Pacific Tropical Weather Outlook
20.05Atlantic Tropical Weather Outlook
20.05We Recycle Solar Expands Partnership with Renewables.org
20.05Washington State Authorizes Drone for Methane Emissions
20.05The Heart, Science & Business of Sustainability: A Fireside Chat with Tara Hemmer
20.05Commissioners Celebrate the Opening of New Waste Transfer Station in Redmond, Ore.
20.05Newhaven Food Waste Facility Plans Paused Following Residents Concerns
20.05Business Report May 2024Highlights from WasteExpo 2024
More »